TY - JOUR
T1 - Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease
AU - Wheeler, Austin M.
AU - Baker, Joshua F.
AU - Poole, Jill A.
AU - Ascherman, Dana P.
AU - Yang, Yangyuna
AU - Kerr, Gail S.
AU - Reimold, Andreas
AU - Kunkel, Gary
AU - Cannon, Grant W.
AU - Wysham, Katherine D.
AU - Singh, Namrata
AU - Lazaro, Deana
AU - Monach, Paul
AU - Bridges, S. Louis
AU - Mikuls, Ted R.
AU - England, Bryant R.
N1 - Funding Information:
AMW is supported by the Rheumatology Research Foundation . BRE is supported by a VA CSR&D ( IK2 CX002203 ) and the Rheumatology Research Foundation. TRM is supported by grants from the VA ( BLR&D Merit I01 BX004660 ), National Institutes of Health ( 2U54GM115458 ), U.S. Department of Defense (PR200793), and the Rheumatology Research Foundation. JFB is supported by a VA CSR&D Merit ( CX0001703 ) and an RR&D Merit ( RX0003644 ). KDW is supported by VA CSR&D ( IK2CX002351 ) and by the Rheumatology Research Foundation. JAP receives funding from the Department of Defense ( PR200793 ) and National Institute for Occupational Safety and Health ( R01OH012045 and U54OH010162 ). NS is supported by the Rheumatology Research Foundation , American Heart Association, and National Institute for Arthritis and Musculoskeletal and Skin Diseases (K23AR079588).
Funding Information:
BRE has consulted for Boehringer-Ingelheim and UpToDate. TRM has consulted for Horizon Therapeutics, Pfizer, Gilead, and Sanofi. GSK has consulted with Janssen, Horizon, UCB, Sanofi, BMS, and Amgen. JAP has received research grant funding from AstraZeneca and clinical research study support form Takeda and GlaxoSmithKline. JFB has received consulting fees from Bristol-Myers Squibb, Pfizer, CorEvitas, and Burns-White, LLC. NS has received consulting fees from Pfizer.
Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - Objective: MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD) in a predominantly Northern European population. We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history. Methods: HLA-DRB1 SE alleles and MUC5B rs35705950 and TOLLIP rs5743890 SNPs were genotyped in U.S. veterans with RA. ILD was validated through medical record review. Genetic associations with ILD were assessed in logistic regression models overall and in subgroups defined by race and smoking status, with additive interactions assessed by the relative excess risk of interaction (RERI). Results: Of 2,556 participants (88% male, 77% White), 238 (9.3%) had ILD. The MUC5B variant was associated with ILD (OR 2.25 [95% CI 1.69, 3.02]), whereas TOLLIP and HLA-DRB1 SE were not. The MUC5B variant was less frequent among Black/African American participants (5.8% vs. 22.6%), though its association with RA-ILD was numerically stronger (OR 4.23 [1.65, 10.86]) compared to all other participants (OR 2.32 [1.70, 3.16]). Those with the MUC5B variant and a smoking history had numerically higher odds of ILD (OR 4.18 [2.53, 6.93]) than non-smokers (OR 2.41 [1.16, 5.04]). Additive interactions between MUC5B-race and MUC5B-smoking were not statistically significant. Conclusion: In this large RA cohort, the MUC5B promoter variant was associated with >2-fold higher odds of RA-ILD. While this variant is less common among Black/African American patients, its presence in this population carried >4-fold higher odds of RA-ILD.
AB - Objective: MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD) in a predominantly Northern European population. We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history. Methods: HLA-DRB1 SE alleles and MUC5B rs35705950 and TOLLIP rs5743890 SNPs were genotyped in U.S. veterans with RA. ILD was validated through medical record review. Genetic associations with ILD were assessed in logistic regression models overall and in subgroups defined by race and smoking status, with additive interactions assessed by the relative excess risk of interaction (RERI). Results: Of 2,556 participants (88% male, 77% White), 238 (9.3%) had ILD. The MUC5B variant was associated with ILD (OR 2.25 [95% CI 1.69, 3.02]), whereas TOLLIP and HLA-DRB1 SE were not. The MUC5B variant was less frequent among Black/African American participants (5.8% vs. 22.6%), though its association with RA-ILD was numerically stronger (OR 4.23 [1.65, 10.86]) compared to all other participants (OR 2.32 [1.70, 3.16]). Those with the MUC5B variant and a smoking history had numerically higher odds of ILD (OR 4.18 [2.53, 6.93]) than non-smokers (OR 2.41 [1.16, 5.04]). Additive interactions between MUC5B-race and MUC5B-smoking were not statistically significant. Conclusion: In this large RA cohort, the MUC5B promoter variant was associated with >2-fold higher odds of RA-ILD. While this variant is less common among Black/African American patients, its presence in this population carried >4-fold higher odds of RA-ILD.
KW - Interstitial lung disease
KW - Rheumatoid arthritis
KW - Single nucleotide polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85138553436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138553436&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2022.152098
DO - 10.1016/j.semarthrit.2022.152098
M3 - Article
C2 - 36155967
AN - SCOPUS:85138553436
SN - 0049-0172
VL - 57
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152098
ER -